These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

508 related articles for article (PubMed ID: 15519609)

  • 1. Toxicology of antisense therapeutics.
    Jason TL; Koropatnick J; Berg RW
    Toxicol Appl Pharmacol; 2004 Nov; 201(1):66-83. PubMed ID: 15519609
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antisense applications for biological control.
    Pan WH; Clawson GA
    J Cell Biochem; 2006 May; 98(1):14-35. PubMed ID: 16440307
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antisense oligonucleotides as therapeutics for malignant diseases.
    Ho PT; Parkinson DR
    Semin Oncol; 1997 Apr; 24(2):187-202. PubMed ID: 9129689
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Making sense of antisense.
    Vidal L; Blagden S; Attard G; de Bono J
    Eur J Cancer; 2005 Dec; 41(18):2812-8. PubMed ID: 16289851
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antisense oligonucleotide-based therapeutics for cancer.
    Dean NM; Bennett CF
    Oncogene; 2003 Dec; 22(56):9087-96. PubMed ID: 14663487
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antisense oligonucleotides: from design to therapeutic application.
    Chan JH; Lim S; Wong WS
    Clin Exp Pharmacol Physiol; 2006; 33(5-6):533-40. PubMed ID: 16700890
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel integrated strategy (full length gene targeting) for mRNA accessible site tagging combined with microarray hybridization/RNase H cleavage to screen effective antisense oligonucleotides.
    Sun Y; Duan M; Lin R; Wang D; Li C; Bo X; Wang S
    Mol Vis; 2006 Nov; 12():1364-71. PubMed ID: 17149362
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antisense oligonucleotide therapy in cancer.
    Stephens AC; Rivers RP
    Curr Opin Mol Ther; 2003 Apr; 5(2):118-22. PubMed ID: 12772500
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antisense treatments for biothreat agents.
    Warfield KL; Panchal RG; Aman MJ; Bavari S
    Curr Opin Mol Ther; 2006 Apr; 8(2):93-103. PubMed ID: 16610760
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of antisense oligonucleotides in the treatment of bladder cancer.
    Duggan BJ; Gray S; Johnston SR; Williamson K; Miyaki H; Gleave M
    Urol Res; 2002 Jul; 30(3):137-47. PubMed ID: 12111175
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Antisense oligonucleotides: a new therapeutic approach].
    Guinot P; Temsamani J
    Pathol Biol (Paris); 1998 May; 46(5):347-54. PubMed ID: 9769897
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antisense molecules for targeted cancer therapy.
    Wacheck V; Zangemeister-Wittke U
    Crit Rev Oncol Hematol; 2006 Jul; 59(1):65-73. PubMed ID: 16750913
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The future of antisense therapy: combination with anticancer treatments.
    Biroccio A; Leonetti C; Zupi G
    Oncogene; 2003 Sep; 22(42):6579-88. PubMed ID: 14528283
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics and biodistribution of phosphorodiamidate morpholino antisense oligomers.
    Amantana A; Iversen PL
    Curr Opin Pharmacol; 2005 Oct; 5(5):550-5. PubMed ID: 16087398
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overcoming biological barriers to in vivo efficacy of antisense oligonucleotides.
    White PJ; Anastasopoulos F; Pouton CW; Boyd BJ
    Expert Rev Mol Med; 2009 Mar; 11():e10. PubMed ID: 19302730
    [TBL] [Abstract][Full Text] [Related]  

  • 17. RNAi: a novel antisense technology and its therapeutic potential.
    Dallas A; Vlassov AV
    Med Sci Monit; 2006 Apr; 12(4):RA67-74. PubMed ID: 16572063
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An overview of sugar-modified oligonucleotides for antisense therapeutics.
    Prakash TP
    Chem Biodivers; 2011 Sep; 8(9):1616-41. PubMed ID: 21922654
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Apoptosis, Bcl-2 antisense, and cancer therapy.
    Piro LD
    Oncology (Williston Park); 2004 Nov; 18(13 Suppl 10):5-10. PubMed ID: 15651171
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro toxicology and pharmacokinetics of antisense oligonucleotides.
    Crooke RM
    Anticancer Drug Des; 1991 Dec; 6(6):609-46. PubMed ID: 1772572
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.